Cytogenetic and molecular testing in patients with chronic myeloid leukemia (CML) in a prospective observational study (SIMPLICITY).

被引：3
|
作者：
Goldberg, Stuart L.
Cortes, Jorge E.
Gambacorti-Passerini, Carlo
Hehlmann, Ruediger
Khoury, Hanna Jean
Mauro, Michael J.
Michallet, Mauricette
Paquette, Ronald
Simonsson, Bengt
Foreman, Aimee
Mohamed, Hesham
Subar, Milayna
Zyczynski, Teresa Maria
机构：
[1] John Theurer Canc Ctr, Hackensack, NJ USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Univ Milano Bicocca, Monza, Italy
[4] Heidelberg Univ, Mannheim, Germany
[5] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[6] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[7] Ctr Hosp Lyon Sud, F-69310 Pierre Benite, France
[8] Ronald Reagan UCLA Med Ctr, Los Angeles, CA USA
[9] Univ Uppsala Hosp, Uppsala, Sweden
[10] ICON Clin Res Biostat & Programming, San Francisco, CA USA
[11] Bristol Myers Squibb, Plainsboro, NJ USA
[12] Medco Hlth Solut Inc, Franklin Lakes, NJ USA
[13] Bristol Myers Squibb Co, Princeton, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.7050
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7050
引用
收藏
页数：1
相关论文
共 50 条
  • [31] SECONDARY MALIGNANCIES IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS
    Enrico, A.
    Pavlovsky, C.
    Mariano, R.
    Moiraghi, B.
    Bendek, G.
    Milone, J.
    HAEMATOLOGICA, 2013, 98 : 551 - 551
  • [32] An Observational Study of Survival in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) After 1, 3, and 5 Years of Tyrosine Kinase Inhibitor (TKI) Therapy (SIMPLICITY)
    Michallet, Mauricette
    Cortes, Jorge
    Gambacorti-Passerini, Carlo
    Hehlmann, Rudiger
    Williams, Loretta A.
    Goldberg, Stuart L.
    Davis, Catherine
    De Solda, Francesco
    Sen, Ginny P.
    Gajavelli, Srikanth
    Mauro, Michael J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S229 - S229
  • [33] Real-Life Experience with Ponatinib in Chronic Myeloid Leukemia (CML): A Multicenter Observational Study
    Abulafia, Adi Shacham
    Raanani, Pia
    Lavie, David
    Volchek, Yulia
    Ram, Ron
    Hellman, Ilana
    Shargian, Liat
    Gourevietch, Anna
    Chubar, Evgeni
    Ratzon, Roy
    Rozovski, Uri
    BLOOD, 2017, 130
  • [34] Molecular Pathogenesis and Treatment Strategies of Chronic Myeloid Leukemia (CML)
    Khalid, Rabia
    Riasat, Sana
    SUDAN JOURNAL OF MEDICAL SCIENCES, 2023, 18 (04): : 525 - 538
  • [35] MOLECULAR-BIOLOGY OF CHRONIC MYELOID-LEUKEMIA (CML)
    GOLDMAN, JM
    ACTA HAEMATOLOGICA, 1987, 78 : 200 - 200
  • [36] A Multicenter, Prospective Study for Pediatric Chronic Myeloid Leukemia in Chronic Phase: The JPLSG CML-08 Study
    Shimada, Hiroyuki
    Watanabe, Akihiro
    Ito, Masaki
    Tono, Chikako
    Shima, Haruko
    Yuza, Yuki
    Muramatsu, Hideki
    Okada, Masahiko
    Tanizawa, Akihiko
    BLOOD, 2021, 138
  • [37] EARLY MOLECULAR RESPONSE TO NILOTINIB IN PATIENTS WHO FAILED IMATINIB IS ASSOCIATED WITH A HIGHER PROBABILITY OF CYTOGENETIC RESPONSE IN CHRONIC MYELOID LEUKEMIA (CML)
    Hughes, T.
    Kim, D.
    Martinelli, G.
    Branford, S.
    Mueller, M.
    Beppu, L.
    Goh, H.
    Soverini, S.
    Shou, Y.
    Reynolds, J.
    Woodman, R.
    Kantarjian, H.
    Saglio, G.
    Radich, J.
    Hochhaus, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 54 - 54
  • [38] PROTEOMIC PROFILE CORRELATES TO MOLECULAR RESPONSE (MR) IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML)
    Sgherza, N.
    Garrisi, V. M.
    Iacobazzi, A.
    Abbate, I.
    Cascavilla, N.
    Guarini, A.
    HAEMATOLOGICA, 2016, 101 : S103 - S104
  • [39] A prospective study in Ph plus chronic myeloid leukemia (CML) patients showing that interphase fluorescence in situ hybridization (FISH) is effective as conventional cytogenetics for definition of cytogenetic response. Correlation with molecular response (by the GIMEMA CML WP).
    Testoni, Nicoletta
    Luatti, S.
    Marzocchi, G.
    Amabile, M.
    Gamberini, C.
    Buontempo, F.
    Baldazzi, C.
    Iacobucci, I.
    Mancini, M.
    Cuneo, A.
    Specchia, G.
    Kerim, S.
    Rege-Cambrin, G.
    Giugliano, E.
    Giussani, U.
    Abruzzese, E.
    Grimoldi, M. G.
    Modaferri, B.
    Castagnetti, F.
    Palandri, F.
    Mecucci, C.
    Bernasconi, P.
    Gozzetti, A.
    Palka, G.
    Zanatta, L.
    Zaccaria, A.
    Martinelli, G.
    Rosti, G.
    Baccarani, Michele
    BLOOD, 2006, 108 (11) : 278B - 278B
  • [40] A pilot study of daily oral idarubicin in patients with chronic myeloid leukemia (CML).
    Giles, FJ
    Wong, GC
    O'Brien, SM
    Cortes, J
    Freireich, E
    Estey, E
    Talpaz, M
    Kantarjian, HM
    Keating, MJ
    BLOOD, 1998, 92 (10) : 244B - 244B
12345